

# Marinos C Dalakas

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/990663/marinos-c-dalakas-publications-by-year.pdf>

**Version:** 2024-04-05

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

202 papers	17,619 citations	72 h-index	129 g-index
224 ext. papers	20,031 ext. citations	10 avg, IF	7.52 L-index

#	Paper	IF	Citations
202	Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies.. <i>Neurotherapeutics</i> , <b>2022</b> , 1	6.4	3
201	IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	11
200	Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases.. <i>Neurotherapeutics</i> , <b>2022</b> , 1	6.4	0
199	Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	5
198	Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies.. <i>Neurotherapeutics</i> , <b>2022</b> , 1	6.4	1
197	Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits.. <i>Expert Review of Clinical Immunology</i> , <b>2022</b> , 18, 413-423	5.1	0
196	Progressive multifocal fibrosing neuropathy: description of a novel disease.. <i>Acta Neuropathologica Communications</i> , <b>2022</b> , 10, 34	7.3	
195	The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies.. <i>Neurotherapeutics</i> , <b>2022</b> , 1	6.4	2
194	Natalizumab therapy in patients with pediatric-onset multiple sclerosis in Greece: clinical and immunological insights of time-long administration and future directions-a single-center retrospective observational study.. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>2022</b> , 1	3.4	0
193	Unconvincing Evidence of SARS-CoV-2-Associated Myositis in Autopsied Muscles. <i>JAMA Neurology</i> , <b>2021</b> ,	17.2	2
192	Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy. <i>Neurotherapeutics</i> , <b>2021</b> , 1	6.4	8
191	Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate: Significance of CD8 and Natural Killer Cells. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2021</b> , 8,	9.1	2
190	Autoimmune Neurogenic Dysphagia. <i>Dysphagia</i> , <b>2021</b> , 1	3.7	0
189	LGI1 encephalitis with squamous lung-cell carcinoma: Resolution after tumor resection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2021</b> , 8,	9.1	1
188	GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2021</b> , 14, 17562864211003486	6.6	11
187	Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 627285	8.4	12
186	Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data. <i>Neurological Sciences</i> , <b>2021</b> , 1	3.5	1

185	The importance of FcRn in neuro-immunotherapies: From IgG catabolism, gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2021</b> , 14, 1756286421997381	6.6	16
184	Anti-SARS-CoV-2 antibody detection in healthcare workers of two tertiary hospitals in Athens, Greece. <i>Clinical Immunology</i> , <b>2020</b> , 221, 108619	9	7
183	Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2020</b> , 7,	9.1	139
182	Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. <i>Acta Myologica</i> , <b>2020</b> , 39, 289-301	1.6	10
181	Anti-Neuronal Antibodies Within the IVIg Preparations: Importance in Clinical Practice. <i>Neurotherapeutics</i> , <b>2020</b> , 17, 235-242	6.4	10
180	Complement in neurological disorders and emerging complement-targeted therapeutics. <i>Nature Reviews Neurology</i> , <b>2020</b> , 16, 601-617	15	49
179	Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2020</b> , 7,	9.1	61
178	Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. <i>Current Opinion in Neurology</i> , <b>2020</b> , 33, 545-552	7.1	20
177	Treatment of Stiff-Person Syndrome. <i>Current Clinical Neurology</i> , <b>2019</b> , 333-335	0.1	1
176	Autoimmune Peripheral Neuropathies <b>2019</b> , 903-915.e1		1
175	Trial of canakinumab, an IL-1 $\beta$ receptor antagonist, in patients with inclusion body myositis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6, e581	9.1	6
174	The immunobiology of autoimmune encephalitides. <i>Journal of Autoimmunity</i> , <b>2019</b> , 104, 102339	15.5	26
173	Case 22-2019: A 65-Year-Old Woman with Myopathy. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1693	59.2	4
172	IVIg efficacy in CIDP patients is not associated with terminal complement inhibition. <i>Journal of Neuroimmunology</i> , <b>2019</b> , 330, 23-27	3.5	10
171	Immunotherapy in myasthenia gravis in the era of biologics. <i>Nature Reviews Neurology</i> , <b>2019</b> , 15, 113-124	5	65
170	Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder. <i>BMC Neurology</i> , <b>2019</b> , 19, 1	3.1	49
169	Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2018</b> , 5, e460	9.1	10
168	Myositis: Are autoantibodies pathogenic in necrotizing myopathy?. <i>Nature Reviews Rheumatology</i> , <b>2018</b> , 14, 251-252	8.1	15

167	Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2018</b> , 11, 1756285617746640	6.6	42
166	Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIP Trial): a double-blind, multicentre, randomised controlled trial. <i>Lancet Neurology</i> , <b>2018</b> , 17, 689-698	24.1	34
165	Use of Intravenous Immunoglobulin in Neurology <b>2018</b> , 101-109		2
164	Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. <i>Lancet Neurology</i> , <b>2018</b> , 17, 20-21	24.1	5
163	Neurological complications of immune checkpoint inhibitors: what happens when you take the brakes off the immune system. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2018</b> , 11, 1756286418799864	6.6	97
162	Postherpes simplex encephalitis: a case series of viral-triggered autoimmunity, synaptic autoantibodies and response to therapy. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2018</b> , 11, 17562864187998778	6.6	23
161	Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2017</b> , 4, e306	9.1	5
160	A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. <i>Annals of Neurology</i> , <b>2017</b> , 82, 271-277	9.4	51
159	Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM. <i>BMC Neurology</i> , <b>2016</b> , 16, 48	3.1	13
158	Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials. <i>Neurotherapeutics</i> , <b>2016</b> , 13, 20-33	6.4	18
157	Efficacy of Intravenous Immunoglobulin in Neurological Diseases. <i>Neurotherapeutics</i> , <b>2016</b> , 13, 34-46	6.4	48
156	Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity. <i>Neurotherapeutics</i> , <b>2016</b> , 13, 163-78	6.4	13
155	Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2016</b> , 9, 69-73	6.6	11
154	Polymyositis <b>2016</b> , 497-500		
153	Inflammatory Muscle Diseases. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 393-4	59.2	110
152	HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis. <i>Experimental Neurology</i> , <b>2015</b> , 271, 189-97	5.7	20
151	Inflammatory muscle diseases. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1734-47	59.2	356
150	GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders. <i>Journal of Neuroimmunology</i> , <b>2015</b> , 281, 73-7	3.5	33

149	Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. <i>Journal of Neuroimmunology</i> , <b>2015</b> , 289, 8-11	3.5	25
148	Reliability of the adult myopathy assessment tool in individuals with myositis. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 563-70	4.7	9
147	Pathogenesis of immune-mediated neuropathies. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2015</b> , 1852, 658-66	6.9	76
146	Treatment for inclusion body myositis. <i>The Cochrane Library</i> , <b>2015</b> ,	5.2	5
145	Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2015</b> , 2, e131	9.1	89
144	Future perspectives in target-specific immunotherapies of myasthenia gravis. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2015</b> , 8, 316-27	6.6	21
143	Intravenous immunoglobulin in neurology--mode of action and clinical efficacy. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 80-9	15	174
142	Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 143-56	15	78
141	Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 4160-70	15.9	158
140	Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4. <i>Autoimmunity</i> , <b>2015</b> , 48, 453-9	3	5
139	Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations. <i>Journal of Clinical Immunology</i> , <b>2014</b> , 34 Suppl 1, S120-6	5.7	27
138	Immunotherapy-responsive limbic encephalitis with antibodies to glutamic acid decarboxylase. <i>Journal of the Neurological Sciences</i> , <b>2014</b> , 343, 192-4	3.2	17
137	Autoimmune encephalitis with GABAB antibodies, thymoma, and GABAB receptor thymic expression. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2014</b> , 1, e39	9.1	15
136	Reduction of Intraepidermal Nerve Fiber Density (IENFD) in the skin biopsies of patients with fibromyalgia: a controlled study. <i>Journal of the Neurological Sciences</i> , <b>2014</b> , 347, 143-7	3.2	60
135	Pathophysiology of autoimmune polyneuropathies. <i>Presse Medicale</i> , <b>2013</b> , 42, e181-92	2.2	21
134	Immunology of stiff person syndrome and other GAD-associated neurological disorders. <i>Expert Review of Clinical Immunology</i> , <b>2013</b> , 9, 1043-53	5.1	50
133	Progress and stiff challenges in understanding the role of GAD-antibodies in stiff-person syndrome. <i>Experimental Neurology</i> , <b>2013</b> , 247, 303-7	5.7	22
132	The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. <i>Journal of the Neurological Sciences</i> , <b>2013</b> , 334, 123-5	3.2	42

131	Novel future therapeutic options in myasthenia gravis. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 936-41	13.6	32
130	Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders. <i>Neurology</i> , <b>2013</b> , 81, 1962-4	6.5	43
129	Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives. <i>Expert Review of Clinical Immunology</i> , <b>2013</b> , 9, 1125-33	5.1	20
128	Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e55843	3.7	63
127	Autoimmune peripheral neuropathies <b>2013</b> , 801-811		
126	Pathogenesis and therapies of immune-mediated myopathies. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, 203-6	13.6	73
125	Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies. <i>Journal of the Peripheral Nervous System</i> , <b>2012</b> , 17 Suppl 2, 34-9	4.7	26
124	Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and ß-amyloid in the muscle. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 4094-103		21
123	Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future. <i>Annals of the New York Academy of Sciences</i> , <b>2012</b> , 1274, 1-8	6.5	15
122	Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1ß-induced accumulation of ß-amyloid and cell death. <i>Brain</i> , <b>2012</b> , 135, 1102-14	11.2	45
121	Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 1393-402	15.9	47
120	Advances in the diagnosis, pathogenesis and treatment of CIDP. <i>Nature Reviews Neurology</i> , <b>2011</b> , 7, 507-17	15.7	172
119	Peripheral neuropathies in Sjogren syndrome: a new reappraisal. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2011</b> , 82, 798-802	5.5	59
118	Pathophysiology of inflammatory and autoimmune myopathies. <i>Presse Medicale</i> , <b>2011</b> , 40, e237-47	2.2	54
117	Inflammatory myopathies: management of steroid resistance. <i>Current Opinion in Neurology</i> , <b>2011</b> , 24, 457-62	7.1	34
116	Potential biomarkers for monitoring therapeutic response in patients with CIDP. <i>Journal of the Peripheral Nervous System</i> , <b>2011</b> , 16 Suppl 1, 63-7	4.7	21
115	Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies. <i>Journal of Neurology</i> , <b>2011</b> , 258, 1568-70	5.5	33
114	Immunotherapy of inflammatory myopathies: practical approach and future prospects. <i>Current Treatment Options in Neurology</i> , <b>2011</b> , 13, 311-23	4.4	35

113	A critical update on the immunopathogenesis of Stiff Person Syndrome. <i>European Journal of Clinical Investigation</i> , <b>2010</b> , 40, 1018-25	4.6	48
112	Inclusion-body myositis in the elderly: an update. <i>Aging Health</i> , <b>2010</b> , 6, 687-694		6
111	Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Archives of Neurology</i> , <b>2010</b> , 67, 802-7		87
110	Inflammatory muscle diseases: a critical review on pathogenesis and therapies. <i>Current Opinion in Pharmacology</i> , <b>2010</b> , 10, 346-52	5.1	86
109	Immunotherapy of myositis: issues, concerns and future prospects. <i>Nature Reviews Rheumatology</i> , <b>2010</b> , 6, 129-37	8.1	123
108	Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. <i>Expert Opinion on Medical Diagnostics</i> , <b>2010</b> , 4, 241-50		16
107	Practical considerations on the use of rituximab in autoimmune neurological disorders. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2010</b> , 3, 93-105	6.6	64
106	Pathogenesis and Treatment of Anti-MAG Neuropathy. <i>Current Treatment Options in Neurology</i> , <b>2010</b> , 12, 71-83	4.4	53
105	Electrophysiologic correlations with clinical outcomes in CIDP. <i>Muscle and Nerve</i> , <b>2010</b> , 42, 492-7	3.4	45
104	Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. <i>Brain</i> , <b>2009</b> , 132, 1536-44	4.2	147
103	Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. <i>Annals of Neurology</i> , <b>2009</b> , 65, 286-93	9.4	229
102	Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. <i>Muscle and Nerve</i> , <b>2009</b> , 39, 448-55	3.4	36
101	Stiff person syndrome: advances in pathogenesis and therapeutic interventions. <i>Current Treatment Options in Neurology</i> , <b>2009</b> , 11, 102-10	4.4	134
100	Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. <i>Journal of Clinical Investigation</i> , <b>2009</b> , 119, 1806-13	15.9	141
99	Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. <i>Lancet Neurology</i> , <b>2008</b> , 7, 136-44	24.1	505
98	Autoimmune peripheral neuropathies <b>2008</b> , 977-994		4
97	High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65/GAD67 in stiff-person syndrome. <i>Biochemical and Biophysical Research Communications</i> , <b>2008</b> , 366, 1-7	3.4	43
96	Invited article: inhibition of B cell functions: implications for neurology. <i>Neurology</i> , <b>2008</b> , 70, 2252-60	6.5	86



95	Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. <i>Brain</i> , <b>2008</b> , 131, 1228-40	11.2	152
94	Therapeutic advances and future prospects in immune-mediated inflammatory myopathies. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2008</b> , 1, 157-66	6.6	10
93	Advances in the pathogenesis and treatment of patients with stiff person syndrome. <i>Current Neurology and Neuroscience Reports</i> , <b>2008</b> , 8, 48-55	6.6	38
92	IVIg in other autoimmune neurological disorders: current status and future prospects. <i>Journal of Neurology</i> , <b>2008</b> , 255 Suppl 3, 12-6	5.5	51
91	B cells as therapeutic targets in autoimmune neurological disorders. <i>Nature Clinical Practice Neurology</i> , <b>2008</b> , 4, 557-67		125
90	Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells. <i>Annals of Neurology</i> , <b>2007</b> , 61, 466-75	9.4	65
89	Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. <i>Annals of Neurology</i> , <b>2007</b> , 61, 476-83	9.4	114
88	Terminal latency index in neuropathy with antibodies against myelin-associated glycoproteins. <i>Muscle and Nerve</i> , <b>2007</b> , 35, 196-202	3.4	32
87	Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues. <i>Nature Clinical Practice Neurology</i> , <b>2007</b> , 3, 36-44		106
86	B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target <b>2006</b> , 112, 57-70		30
85	Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. <i>Brain</i> , <b>2006</b> , 129, 3270-6	11.2	99
84	Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies. <i>Nature Clinical Practice Neurology</i> , <b>2006</b> , 2, 437-47		162
83	Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. <i>Neurology</i> , <b>2006</b> , 67, 1068-70	6.5	80
82	Inflammatory, immune, and viral aspects of inclusion-body myositis. <i>Neurology</i> , <b>2006</b> , 66, S33-8	6.5	77
81	Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. <i>Nature Clinical Practice Rheumatology</i> , <b>2006</b> , 2, 219-27		84
80	Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. <i>Neuromuscular Disorders</i> , <b>2006</b> , 16, 223-36	2.9	50
79	Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. <i>Brain</i> , <b>2005</b> , 128, 1887-96	11.2	132
78	Brain gamma-aminobutyric acid changes in stiff-person syndrome. <i>Archives of Neurology</i> , <b>2005</b> , 62, 970-4		66



77	Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2005</b> , 29, 255-69	12.3	15
76	Gene expression profiling in chronic inflammatory demyelinating polyneuropathy. <i>Journal of Neuroimmunology</i> , <b>2005</b> , 159, 203-14	3.5	38
75	The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. <i>Journal of Neurology</i> , <b>2005</b> , 252 Suppl 1, I19-25	5.5	53
74	A neuropsychological assessment of phobias in patients with stiff person syndrome. <i>Neurology</i> , <b>2005</b> , 64, 1961-3	6.5	46
73	Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. <i>Journal of Immunology</i> , <b>2005</b> , 175, 7755-62	5.3	118
72	Intravenous immunoglobulin in autoimmune neuromuscular diseases. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 291, 2367-75	27.4	214
71	Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. <i>Archives of Neurology</i> , <b>2004</b> , 61, 902-4		97
70	Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. <i>Brain</i> , <b>2004</b> , 127, 1182-90	11.2	72
69	The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile <b>2004</b> , 102, 177-93		169
68	Basic principles of immunotherapy for neurologic diseases. <i>Seminars in Neurology</i> , <b>2003</b> , 23, 121-32	3.2	18
67	Therapeutic approaches in patients with inflammatory myopathies. <i>Seminars in Neurology</i> , <b>2003</b> , 23, 199-206	3.2	40
66	Stiff-person Syndrome. <i>Current Treatment Options in Neurology</i> , <b>2003</b> , 5, 79-90	4.4	68
65	Immunotherapy in autoimmune neuromuscular disorders. <i>Lancet Neurology</i> , <b>2003</b> , 2, 22-32	24.1	39
64	Expression of IFN-gamma-inducible chemokines in inclusion body myositis. <i>Journal of Neuroimmunology</i> , <b>2003</b> , 141, 125-31	3.5	60
63	Polymyositis and dermatomyositis. <i>Lancet, The</i> , <b>2003</b> , 362, 971-82	40	1051
62	Blockade of blocking antibodies in Guillain-Barré syndromes: "unblocking" the mystery of action of intravenous immunoglobulin. <i>Annals of Neurology</i> , <b>2002</b> , 51, 667-9	9.4	16
61	Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. <i>Neurology</i> , <b>2002</b> , 59, S13-21	6.5	115
60	Immune mechanisms in chronic inflammatory demyelinating neuropathy. <i>Neurology</i> , <b>2002</b> , 59, S7-12	6.5	56

- 59 Peripheral neuropathy and antiretroviral drugs. *Journal of the Peripheral Nervous System*, **2001**, 6, 14-20 4.7 171
- 58 Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. *Annals of Neurology*, **2001**, 50, 195-201 9.4 476
- 57 High-dose intravenous immune globulin for stiff-person syndrome. *New England Journal of Medicine*, **2001**, 345, 1870-6 59.2 317
- 56 Motor cortex excitability in stiff-person syndrome. *Brain*, **2000**, 123 ( Pt 11), 2231-9 11.2 108
- 55 Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. *Clinical Immunology*, **2000**, 94, 99-104 9 101
- 54 Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. *Muscle and Nerve*, **1999**, 22, 1479-97 3.4 159
- 53 Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. *American Journal of Pathology*, **1999**, 155, 453-60 5.8 100
- 52 The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. *Annals of Internal Medicine*, **1999**, 131, 522-30 8 148
- 51 Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers. *Current Opinion in Neurology*, **1999**, 12, 403-9 7.1 38
- 50 Rimmed vacuoles with beta-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (postpoliomyelitis muscular atrophy): similarities with inclusion body myositis. *Human Pathology*, **1998**, 29, 1128-33 3.7 47
- 49 Molecular immunology and genetics of inflammatory muscle diseases. *Archives of Neurology*, **1998**, 55, 1509-12 95
- 48 A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. *Journal of Experimental Medicine*, **1997**, 186, 967-72 16.6 234
- 47 Intravenous immune globulin therapy for neurologic diseases. *Annals of Internal Medicine*, **1997**, 126, 721-30 8 168
- 46 Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. *Annals of Neurology*, **1997**, 41, 100-4 9.4 45
- 45 Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. *Muscle and Nerve*, **1997**, 20, 1102-7 3.4 57
- 44 Reply: Meningitis and Skin Reaction after Intravenous Immune Globulin Therapy. *Annals of Internal Medicine*, **1997**, 127, 1130 8 11
- 43 Inclusion body myositis in HIV-1 and HTLV-1 infected patients. *Brain*, **1996**, 119 ( Pt 6), 1887-93 11.2 112
- 42 Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barré syndrome, myasthenia gravis and dermatomyositis. *Journal of Neuroimmunology*, **1996**, 71, 227-9 3.5 38

41	MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>1996</b> , 55, 1205-9	3.1	72
40	A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. <i>Annals of Neurology</i> , <b>1996</b> , 40, 792-5	9.4	166
39	Role of the muscle in acute poliomyelitis infection. <i>Annals of the New York Academy of Sciences</i> , <b>1995</b> , 753, 58-67	6.5	6
38	Progression of oral-motor and swallowing symptoms in the post-polio syndrome. <i>Annals of the New York Academy of Sciences</i> , <b>1995</b> , 753, 87-95	6.5	13
37	Pathogenetic mechanisms of post-polio syndrome: morphological, electrophysiological, virological, and immunological correlations. <i>Annals of the New York Academy of Sciences</i> , <b>1995</b> , 753, 167-85	6.5	89
36	A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. <i>Annals of the New York Academy of Sciences</i> , <b>1995</b> , 753, 296-302	6.5	42
35	A double-blind, placebo-controlled trial of high-dose prednisone for the treatment of post-poliomyelitis syndrome. <i>Annals of the New York Academy of Sciences</i> , <b>1995</b> , 753, 303-13	6.5	36
34	How to design a therapeutic study in patients with the post-polio syndrome. Methodological concerns and status of present therapies. <i>Annals of the New York Academy of Sciences</i> , <b>1995</b> , 753, 314-20	6.5	2
33	Concluding Remarks and Future Strategies. <i>Annals of the New York Academy of Sciences</i> , <b>1995</b> , 753, 366-369		
32	Common variable immunodeficiency and inclusion body myositis: a distinct myopathy mediated by natural killer cells. <i>Annals of Neurology</i> , <b>1995</b> , 37, 806-10	9.4	29
31	Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. <i>Annals of Neurology</i> , <b>1995</b> , 37 Suppl 1, S2-13	9.4	46
30	Immunopathogenesis of inflammatory myopathies. <i>Annals of Neurology</i> , <b>1995</b> , 37 Suppl 1, S74-86	9.4	174
29	Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. <i>Annals of Neurology</i> , <b>1995</b> , 38, 218-24	9.4	137
28	Identification of macrophages in the muscle biopsy preparations: a comparative study using specific monoclonal antimacrophage antibodies and acid phosphatase reaction. <i>Muscle and Nerve</i> , <b>1995</b> , 18, 242-4	3.4	6
27	Aseptic Meningitis and Intravenous Immunoglobulin Therapy. <i>Annals of Internal Medicine</i> , <b>1995</b> , 122, 316	8	6
26	Neuroimmunotherapy: a practical approach to the treatment of immune-mediated neurologic diseases. <i>Seminars in Neurology</i> , <b>1994</b> , 14, 97-105	3.2	6
25	Polymyositis in patients infected with human T-cell leukemia virus type I: the role of the virus in the cause of the disease. <i>Annals of Neurology</i> , <b>1994</b> , 36, 643-9	9.4	66
24	Current treatment of the inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , <b>1994</b> , 6, 595-601	5.3	35

23	A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. <i>New England Journal of Medicine</i> , <b>1993</b> , 329, 1993-2000	59.2	848
22	Search for HIV proviral DNA and amplified sequences in the muscle biopsies of patients with HIV polymyositis. <i>Muscle and Nerve</i> , <b>1993</b> , 16, 408-13	3.4	43
21	Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 1380-4	59.2	264
20	Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Neurological Sciences</i> , <b>1992</b> , 107, 111-21	3.2	142
19	Sensory neuropathy associated with monoclonal immunoglobulin M to GD1b ganglioside. <i>Annals of Neurology</i> , <b>1992</b> , 31, 683-5	9.4	86
18	Immunocytochemical and virological characteristics of HIV-associated inflammatory myopathies: similarities with seronegative polymyositis. <i>Annals of Neurology</i> , <b>1991</b> , 29, 474-81	9.4	125
17	Dysphagia in patients with the post-polio syndrome. <i>New England Journal of Medicine</i> , <b>1991</b> , 324, 1162-7	59.2	77
16	A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. <i>Medicine (United States)</i> , <b>1991</b> , 70, 360-74	1.8	701
15	Polymyositis, dermatomyositis and inclusion-body myositis. <i>New England Journal of Medicine</i> , <b>1991</b> , 325, 1487-98	59.2	716
14	Mitochondrial myopathy caused by long-term zidovudine therapy. <i>New England Journal of Medicine</i> , <b>1990</b> , 322, 1098-105	59.2	757
13	Neuromuscular diseases associated with human immunodeficiency virus infection. <i>Annals of Neurology</i> , <b>1988</b> , 23 Suppl, S38-48	9.4	196
12	Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies. <i>Muscle and Nerve</i> , <b>1988</b> , 11, 1169-76	3.4	118
11	Chronic idiopathic ataxic neuropathy. <i>Annals of Neurology</i> , <b>1986</b> , 19, 545-54	9.4	116
10	A long-term follow-up study of patients with post-poliomyelitis neuromuscular symptoms. <i>New England Journal of Medicine</i> , <b>1986</b> , 314, 959-63	59.2	306
9	Polymyositis Associated With AIDS Retrovirus. <i>JAMA - Journal of the American Medical Association</i> , <b>1986</b> , 256, 2381	27.4	156
8	Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups. <i>Annals of Neurology</i> , <b>1985</b> , 18, 655-9	9.4	169
7	Tremor as a feature of chronic relapsing and dysgammaglobulinemic polyneuropathies. Incidence and management. <i>Archives of Neurology</i> , <b>1984</b> , 41, 711-4		79
6	Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis. <i>Muscle and Nerve</i> , <b>1983</b> , 6, 182-6	3.4	50

5	Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. <i>Annals of Neurology</i> , <b>1981</b> , 9 Suppl, 134-45	9.4	247
4	Inflammatory myopathies427-452		8
3	Enteroviruses and Human Neuromuscular Diseases387-398		12
2	Polymyositis469-473		
1	Inflammatory and Autoimmune Features of Inclusion-Body Myositis146-158		1